Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1567-1574

  Osterborg, A ^a   Dyer, M J ^a   Bunjes, D ^a   Pangalis, G A ^a   Bastion, Y ^a   Catovsky, D ^a   Mellstedt, H ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTIHISTAMINIC AGENT; CHLORAMBUCIL; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; PETHIDINE; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RASH; RIGOR; TREATMENT OUTCOME;

EID: 0030897222     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1567     Document Type: Article

References (30)

1. Catovsky D, Richards S, Fooks J, et al: CLL trials in the United Kingdom. The Medical Research Council CLL trials 1, 2 and 3. Leuk Lymph 6:105-112, 1991 (suppl)
2. Keating MJ, Kantarjian H, O'Brien S, et al: Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9:44-49, 1991
3. Saven A, Lemon RH, Kosty M, et al: 2-Chlorodeoxy-adenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 13:570-574, 1995
4. Keating MJ, Kantarjian H, Talpaz M, et al: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74:19-25, 1989
5. Juliusson G, Liliemark J: High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 11:679-689, 1993
6. Keating MJ, O'Brien S, Kantarjian H, et al: Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81:2878-2884, 1993
7. Juliusson G, Liliemark J: Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: No aquired resistance. Leuk Lymph 13:75-80, 1994
8. Riechmann L, Clark M, Waldmann H, et al: Reshaping human antibodies for therapy. Nature 332:323-327, 1988
9. Dyer MJS, Hale G, Marcus R, et al: Remission induction in patients with lymphoid malignancies using unconjugated CAMPATH-1 monoclonal antibodies. Leuk Lymph 2:179-193, 1990
10. Salisbury JR, Rapson NT, Codd JD, et al: Immunohistochemical analysis of CDW52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol 47:313-317, 1994
11. Hale G, Dyer MJS, Clark MR, et al: Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody Campath-1H. Lancet 1:1394-1399, 1988
12. Lim SH, Davey G, Marcus R: Differential response in a patient treated with Campath-1H monoclonal antibody for refractory non-Hodgkin lymphoma. Lancet 341:432-433, 1993
13. Dyer MJS, Barge R, Matutes E, et al: Successful treatment of T-cell prolymphocytic leukaemia (T-PLL) with human CD52 antibody, Campath-1H. Br J Haematol 90:76, 1995 (abstr; suppl)
14. Cheson BD, Bennet JM, Rai KR, et al: Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored Working Group. Am J Hematol 29:152-163, 1988
15. Rai KR, Sawitsky A, Cronkite EP, et al: Clinical staging of chronic lymphocytic leukemia. Blood 46:219-234, 1975
16. Sorensen JM, Vena D, Fallavollita A, et al: Treatment of refractory chronic lymphocytic leukemia (CLL) with fludarabine monophosphate (FAMP) under the group C protocol. Proc Am Soc Clin Oncol 11:264, 1992 (abstr)
17. Saven A, Carrera CJ, Carson DA, et al: 2-Chloradeoxyade-nosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymph 5:133-134, 1991
18. Pott-Hoeck C, Hiddemann W: Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias. Ann Oncol 6:421-433, 1995
19. Tallman MS, Hakimian D: Purine nucleoside analogs: Emerging roles in indolent lymphoproliferative disorders. Blood 86:2463-2474, 1995
20. Hale G, Clark M, Waldmann H: Therapeutic potential of rat monoclonal antibodies. Isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol 134:3056-3061, 1985
21. Xia MQ, Hale G, Waldmann H: Efficient complement-mediated lysis of cells containing the Campath-1H (CDw52) antigen. Mol Immunol 30:1089-1096, 1993
22. Gilleece MH, Dexter TM: Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 82:807-812, 1993
23. Shetye J, Frödin J-E, Christensson B, et al: Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb17-1A). Cancer Immunol Immunother 27:154-162, 1988
24. Österborg A, Fassas A, Anagnostopoulos A, et al: Humanised CD52 monoclonal antibody CAMPATH-1H as first line treatment in chronic lymphocytic leukaemia. Br J Haematol 93:151-153, 1996.
25. Maloney DG, Bodkin D, Grillo-Lopez AJ, et al: IDEC-28: Final report on a phase II trial in relapsed non-Hodgkin's lymphoma. Blood 84:169a, 1994 (suppl 1, abstr)
26. Caulfield MJ, Murthy S, Tubbs RR, et al: Treatment of chronic lymphocytic leukemia with an anti-idiotypic monoclonal antibody. Clev Clin J Med 56:182-188, 1989
27. Maloney DG, Brown S, Czerwinski DK, et al: Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 80:1502-1510, 1992
28. Hale G, Hoang T, Prospero T, et al: Removal of T cells from bone marrow for transplantation: Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes. Mol Biol Med 1:305-311, 1983
29. Isaacs JD, Watts RA, Hazleman BL, et al: Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340:748-752, 1992
30. Rai KR, Hoffman M, Janson D, et al: Immunosuppression and opportunistic infections (OI) in patients with chronic lymphocytic leukemia (CLL) following Campath-1H therapy. Blood 86:348a, 1995 (suppl 1, abstr)